ARS Pharmaceuticals is a biopharmaceutical company focused on utilizing its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Co. has engineered SBT8230 to treat chronic hepatitis B virus by eliciting an anti-viral immune response through targeting TLR8 activation to the liver. SBT8230 is comprised of an ASGR1 monoclonal antibody conjugated to the same TLR8 linker-payload as SBT6050, but with an average drug antibody ratio (DAR) of about two as opposed to the average DAR of about four used in SBT6050. We show 6 historical shares outstanding datapoints in our SPRY shares outstanding history coverage, used to compute SPRY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SPRY market cap history over the course of time is important for investors
interested in comparing SPRY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SPRY versus a peer is one thing; comparing
SPRY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SPRY can fluctuate over the course of history.
With this page we aim to empower investors researching SPRY by allowing them to research the SPRY market cap history. |
Free SPRY Email Alerts:
Video: The Importance of Market Cap
